PLEXION NS
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- PLEXION NS
- Generic name
- SULFACETAMIDE SODIUM
- Manufacturer
- Eckson Labs, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- cdb4c921-e671-6f06-e053-2995a90abd1e
- SPL ID
- d7af39fc-190c-6c97-e053-2995a90adc80
- Version
- 3
- Effective date
- 2022-02-10
- Source export date
- 2026-11-13
- Source partition
- 5
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0005-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/e10f1fd48195fb7eda0be611a6e3c49a40fe34c69a9c2a8d9e3e3b897ac31621/drug-label-0005-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:12:33
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | PLEXION NS | openfda.brand_name | |
| generic name | SULFACETAMIDE SODIUM | openfda.generic_name | |
| manufacturer name | Eckson Labs, LLC | openfda.manufacturer_name | |
| ndc | package | 44118-712-08 | openfda.package_ndc |
| ndc | product | 44118-712 | openfda.product_ndc |
| ndc11 | package | 44118071208 | derived:openfda.package_ndc |
| rxcui | 2571664 | openfda.rxcui | |
| spl id | d7af39fc-190c-6c97-e053-2995a90adc80 | id | |
| spl set id | cdb4c921-e671-6f06-e053-2995a90abd1e | set_id | |
| unii | 4NRT660KJQ | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF REACH OF CHILDREN.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.